Delivery and Implementation of a Randomised Crossover Trial on Thrombosis

NANot yet recruitingINTERVENTIONAL
Enrollment

21,194

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Hip FracturesVenous Thromboembolism (VTE)
Interventions
DRUG

Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.

Unlike low molecular weight heparin (LMWH), which requires daily subcutaneous injections, aspirin is taken orally, making it more comfortable and acceptable for patients, particularly the elderly or those with mobility issues. Aspirin is significantly less expensive than injectable anticoagulants like LMWH or newer oral anticoagulants, making it a potentially cost-effective alternative for thromboprophylaxis.

DRUG

Low molecular weight heparin (LMWH)

"LMWH is administered via daily subcutaneous injection, typically starting shortly after surgery and continued for a defined period as per each hospital's local policy, often 14 to 28 days. LMWH has a proven track record of reducing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) after surgery.~However, it carries a risk of bleeding and may be challenging for some frail or elderly patients to tolerate, especially if self-injection is required post-discharge."

All Listed Sponsors
lead

Queen Mary University of London

OTHER

NCT06937372 - Delivery and Implementation of a Randomised Crossover Trial on Thrombosis | Biotech Hunter | Biotech Hunter